MedTrace Logo

Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease

NCT00967681 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-05-04

No results posted yet for this study

Summary

The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.

Conditions

  • Breast Fibrocystic Disease

Interventions

DIETARY_SUPPLEMENT

Oncoxin

(caplets 300 mg), three oral caplets per day for 24 weeks

DIETARY_SUPPLEMENT

Placebo

(caplets 300 mg), three oral caplets per day for 24 weeks

Sponsors & Collaborators

  • Catalysis SL

    lead INDUSTRY

Principal Investigators

  • Daisy Hernández, MD · Ramón González Coro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967681 on ClinicalTrials.gov